<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433586</url>
  </required_header>
  <id_info>
    <org_study_id>2015D006250</org_study_id>
    <secondary_id>K01HL130625</secondary_id>
    <nct_id>NCT03433586</nct_id>
  </id_info>
  <brief_title>COMT on Aspirin Platelets Effects (CAPE)</brief_title>
  <acronym>CAPE</acronym>
  <official_title>COMT on Aspirin Platelets Effects (CAPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim I: Examine the role of genetic variation in COMT on platelet function in a&#xD;
      blinded, randomized, placebo controlled clinical trial of daily placebo or Aspirin (81mg) for&#xD;
      10 ± 3 days. Platelet function will be assessed with platelet aggregometry and by&#xD;
      fluorescence-activated cell sorting (FACS) of platelet adhesion molecules P-selectin and&#xD;
      GPIIb/IIIa in platelets activated with arachidonic acid, thrombin, collagen, epinephrine and&#xD;
      ADP.&#xD;
&#xD;
      Specific Aim II: Examine the effects of platelet releasates harvested at the end of each&#xD;
      treatment arm on angiogenesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blinded, placebo controlled study. This study is designed to&#xD;
      detect the variation in platelet function based on COMT variation and how these platelets&#xD;
      respond to cancerous cells.&#xD;
&#xD;
      We expect to recruit 60 healthy participants with the intention of studying 45 participants&#xD;
      to complete the protocol.&#xD;
&#xD;
      Individuals aged 18 to 40 years will be eligible to participate in this study if they do not&#xD;
      have history of fainting/problems related to blood draws, major chronic medical illnesses,&#xD;
      regular or current treatment of Aspirin™.&#xD;
&#xD;
      Examine the role of genetic variation in in catechol-O-methyltransferase (COMT) on platelet&#xD;
      function in a randomized double-blinded placebo controlled clinical trial of daily Aspirin™&#xD;
      (81 mg) versus placebo over 10-14 days. Platelet function will be assessed with a platelet&#xD;
      aggregometry and by fluorescence-activated cell sorting assessment of platelet adhesion&#xD;
      molecule GPIIIb/IIIa and p-selectin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>participants will be randomized to aspirin or placebo</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>platelet aggregation</measure>
    <time_frame>At end of treatment 10-14 days the platelets will be activated on the same day as blood collection.</time_frame>
    <description>Platelets will be activated with arachidonic acid, thrombin, collagen, ADP and epinephrine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% expression of P-selectin on resting and activated platelets</measure>
    <time_frame>At end of treatment 10-14 days the platelets will be activated on the same day as blood collection.</time_frame>
    <description>Platelets activated with arachidonic acid, ADP, collagen and epinephrine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin (81mg) will be taken orally daily for 10-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>81mg of aspirin to be taken daily for 10-14 days</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy, 18-40 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  taking aspirin. Smoking, pregnancy, history of cancer of cardiovascular disease.&#xD;
             Mental illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn T Hall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn T Hall, PhD</last_name>
    <phone>617 278 0938</phone>
    <email>khall0@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elaine Zaharris</last_name>
    <phone>617 278 0472</phone>
    <email>ezaharris@rics.bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Hall, PhD</last_name>
      <phone>617-278-0938</phone>
      <email>khall0@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Harvey Roweth, PhD</last_name>
      <email>hroweth@bwh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hall KT, Nelson CP, Davis RB, Buring JE, Kirsch I, Mittleman MA, Loscalzo J, Samani NJ, Ridker PM, Kaptchuk TJ, Chasman DI. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2160-7. doi: 10.1161/ATVBAHA.114.303845. Epub 2014 Jul 17.</citation>
    <PMID>25035343</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Kathryn Tayo Hall</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The generation of large-scale human or non-human genome data is not an explicit plan in this proposal. However, any genomic data as it pertains to single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, or gene expression data produced from the work in this award will be made publicly available through the appropriate NIH data repositories including array express, Database of Genotypes and Phenotypes (dbGaP), Database of Short Genetic Variations (dbSNP) or Gene Expression Omnibus (GEO). We intend to share the results from this study in published manuscripts and presentations at National Meetings. Unique methodology or results developed or generated through this study will be made readily available for research purposes to qualified individuals within the scientific community. Interested researchers will be able to contact the corresponding authors of the publications for information about access to resources.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

